53308-23-9

Basic information

• Product Name: 1,4-dihydro-1,4-methanonaphthalen-5-yl methyl ether
• Synonyms: 1,4-Methanonaphthalene, 1,4-dihydro-5-methoxy-
• CAS NO: 53308-23-9
• Molecular Formula: C₁₂H₁₂O
• Molecular Weight: 172.2231
• Mol File: 53308-23-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 250.7°C at 760 mmHg
• Flash Point: 94.3°C
• Density: 1.13g/cm³
• Vapor Pressure: 0.0339mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: 1,4-dihydro-1,4-methanonaphthalen-5-yl methyl ether(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dihydro-1,4-methanonaphthalen-5-yl methyl ether(53308-23-9)
• EPA Substance Registry System: 1,4-dihydro-1,4-methanonaphthalen-5-yl methyl ether(53308-23-9)

Safety Data

• Hazardous Substances Data: 53308-23-9(Hazardous Substances Data)

Upstream product

• 446-59-3 2‐bromo‐1‐fluoro‐3‐methoxybenzene 
• 542-92-7 cyclopenta-1,3-diene 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 7079-54-1 1-fluoro-2-iodo-3-methoxybenzene 

Relevant articles and documents

Binding Requirements of Phenolic Phenylethylamines in the Benzonorbornene Skeleton at the Active Site of Phenylethanolamine N-Methyltransferase

In order to determine the active site binding orientation of norepinephrine, a series of conformationally defined analogues of the tyramines, in which the ethylamine side chain is held fixed by incorporation into a benzonorbornene skeleton, were prepared and evaluated for phenylethanolamine N-methyltransferase (PNMT) activity.While exo-2-amino-5- and exo-2-amino-8-hydroxybenzonorbornene (7 and 10, respectively) were prepared from 5-methoxybenzonorbornadiene by azidomercuration / demercuration and reduction, it was necessary to employ both normal (inversion ofconfiguration) and abnormal (retention of configuration) Mitsunobu reactions to prepare, stereoselectively, exo-2-amino-6- and exo-2-amino-7-hydroxybenzonorbornene (8 and 9, respectively) from 6- and 7-methoxybenzonorbornen-2-ol.None of the six analogues were substrates.However, exo-2-amino-6-hydroxybenzonorbornene (8) and anti-9-amino-6-hydroxybenzonorbornene (12) displayed signifficant activity as inhibitors toward PNMT.The greater potency of 8 and 12, as compared to the parent unsubstituted analogues exo-2-amino- and anti-9-amino-benzonorbornene (4 and 5, respectively), indicates the presence of a spatially compact hydrophilic pocket within the aromatic ring binding region of the active site of the enzyme.Furthermore, the greater activity of 12, relative to 8, is consistent with an active site binding preference for molecules in which a more coplanar relationship exists between the aromatic ring and the amine nitrogen.From the findings of this study, it appears that norephinephrine has a different active site binding orientation than most known substrates and competitive inhibitors of PNMT.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.